Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma. Risks include near-term dilution, potential competitive pressures from Replimune's RP1 approval, and evolving data in lung cancer and sarcoma, but current valuation reflects these concerns. This idea was discussed in more depth with members of my private investing community, ROTY Biotech Community. Learn More » koto_feja/E+ via Getty Images Shares of Iovance Biotherapeutics ( IOVA ) have lost nearly two-thirds of their value since Amtagvi was approved in February 2024. On the other hand, shares were up by as much as 80% YTD mid-March due to increasing enthusiasm for More on my IG service Take a 2 Week Free
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help [Seeking Alpha]Seeking Alpha
- Iovance Biotherapeutics (IOVA) was upgraded by Truist Financial Corporation to "hold".MarketBeat
- Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 3/11/26 - Form 4
- IOVA's page on the SEC website